While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

A study finds that adjunctive use of GLP-1 receptor agonists before and after undergoing bariatric surgery produces greater ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in ...

Popular GLP-1 drugs help many people drop tremendous amounts of weight, but the drugs fail to provide a key improvement in ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

GLP-1 drugs came out in 2005 as a Type 2 diabetes treatment. But in recent years their popularity for weight loss -- and the ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...

Studies presented at the Society of Neurointerventional Surgery’s show links between GLP-1s and the prevention of strokes and ...

Wraparound care for patients taking GLP-1 agonists must include assessment of nutritional status to identify the risk of malnutrition, writes Ellen Fallows Food insecurity is increasing, particularly ...